Harrell Investment Partners LLC Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Harrell Investment Partners LLC acquired a new position in Thermo Fisher Scientific, buying 1,691 shares valued at approximately $686,000, according to a recent SEC filing.
• Thermo Fisher Scientific recently reported quarterly earnings, with **$5.36 earnings per share (EPS)**, surpassing estimates, and a revenue of **$10.86 billion**, up **2.9%** from the previous year.
• The company announced a quarterly dividend of **$0.43**, which will be paid on **October 15th**, contributing to an annualized yield of **0.4%**.

Harrell Investment Partners LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,691 shares of the medical research company's stock, valued at approximately $686,000.

A number of other large investors have also added to or reduced their stakes in TMO. GAMMA Investing LLC grew its position in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the period. Nuveen LLC bought a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $532,360,000. Sarasin & Partners LLP bought a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $242,991,000. EdgePoint Investment Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $172,139,000. Finally, Cohen Investment Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after acquiring an additional 331,180 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 0.4%

TMO opened at $467.91 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The firm's fifty day moving average is $475.04 and its 200 day moving average is $448.83. The stock has a market cap of $176.69 billion, a price-to-earnings ratio of 27.06, a price-to-earnings-growth ratio of 2.55 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. HSBC reiterated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $490.00 to $550.00 in a research note on Thursday, September 11th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Sixteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.